These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31198944)

  • 1. Single-Dose Mucosal Immunotherapy With Chimpanzee Adenovirus-Based Vaccine Accelerates Tuberculosis Disease Control and Limits Its Rebound After Antibiotic Cessation.
    Afkhami S; Lai R; D'agostino MR; Vaseghi-Shanjani M; Zganiacz A; Yao Y; Jeyanathan M; Xing Z
    J Infect Dis; 2019 Sep; 220(8):1355-1366. PubMed ID: 31198944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis.
    Wang J; Thorson L; Stokes RW; Santosuosso M; Huygen K; Zganiacz A; Hitt M; Xing Z
    J Immunol; 2004 Nov; 173(10):6357-65. PubMed ID: 15528375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene-based neonatal immune priming potentiates a mucosal adenoviral vaccine encoding mycobacterial Ag85B.
    Dai G; Rady HF; Huang W; Shellito JE; Mason C; Ramsay AJ
    Vaccine; 2016 Dec; 34(50):6267-6275. PubMed ID: 27823900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen.
    Santosuosso M; Zhang X; McCormick S; Wang J; Hitt M; Xing Z
    J Immunol; 2005 Jun; 174(12):7986-94. PubMed ID: 15944305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization.
    Xing Z; Lichty BD
    Tuberculosis (Edinb); 2006; 86(3-4):211-7. PubMed ID: 16504584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential pulmonary immunization with heterologous recombinant influenza A virus tuberculosis vaccines protects against murine M. tuberculosis infection.
    Muflihah H; Flórido M; Lin LCW; Xia Y; Triccas JA; Stambas J; Britton WJ
    Vaccine; 2018 Apr; 36(18):2462-2470. PubMed ID: 29602704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human type 5 adenovirus-based tuberculosis vaccine: is the respiratory route of delivery the future?
    Smaill F; Xing Z
    Expert Rev Vaccines; 2014 Aug; 13(8):927-30. PubMed ID: 24935214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of an Immune-Protective T-Cell Repertoire With Diverse Genetic Coverage by a Novel Viral-Vectored Tuberculosis Vaccine in Humans.
    Jeyanathan M; Damjanovic D; Yao Y; Bramson J; Smaill F; Xing Z
    J Infect Dis; 2016 Dec; 214(12):1996-2005. PubMed ID: 27703038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis.
    Santosuosso M; McCormick S; Zhang X; Zganiacz A; Xing Z
    Infect Immun; 2006 Aug; 74(8):4634-43. PubMed ID: 16861651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the fusion design and immunization route on the immunogenicity of Ag85A-Mtb32 in adenoviral vectored tuberculosis vaccine.
    Zhang Y; Feng L; Li L; Wang D; Li C; Sun C; Li P; Zheng X; Liu Y; Yang W; Niu X; Zhong N; Chen L
    Hum Vaccin Immunother; 2015; 11(7):1803-13. PubMed ID: 26076321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of Homologous and Heterologous Prime-Boost Immunization Regimens of Recombinant Adenovirus and Modified Vaccinia Virus Ankara Expressing an Ag85B-TB10.4 Fusion Protein against
    Kou Y; Wan M; Shi W; Liu J; Zhao Z; Xu Y; Wei W; Sun B; Gao F; Cai L; Jiang C
    J Microbiol Biotechnol; 2018 Jun; 28(6):1022-1029. PubMed ID: 29847865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AdHu5Ag85A Respiratory Mucosal Boost Immunization Enhances Protection against Pulmonary Tuberculosis in BCG-Primed Non-Human Primates.
    Jeyanathan M; Shao Z; Yu X; Harkness R; Jiang R; Li J; Xing Z; Zhu T
    PLoS One; 2015; 10(8):e0135009. PubMed ID: 26252520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization with a bivalent adenovirus-vectored tuberculosis vaccine provides markedly improved protection over its monovalent counterpart against pulmonary tuberculosis.
    Mu J; Jeyanathan M; Small CL; Zhang X; Roediger E; Feng X; Chong D; Gauldie J; Xing Z
    Mol Ther; 2009 Jun; 17(6):1093-100. PubMed ID: 19319120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrapulmonary (i.pulmon.) Pull Immunization With the Tuberculosis Subunit Vaccine Candidate H56/CAF01 After Intramuscular (i.m.) Priming Elicits a Distinct Innate Myeloid Response and Activation of Antigen-Presenting Cells Than i.m. or i.pulmon. Prime Immunization Alone.
    Thakur A; Pinto FE; Hansen HS; Andersen P; Christensen D; Janfelt C; Foged C
    Front Immunol; 2020; 11():803. PubMed ID: 32457748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A recombinant adenovirus expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis elicits strong antigen-specific immune responses in mice.
    Li W; Deng G; Li M; Zeng J; Zhao L; Liu X; Wang Y
    Mol Immunol; 2014 Nov; 62(1):86-95. PubMed ID: 24980867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon.
    Radosevic K; Wieland CW; Rodriguez A; Weverling GJ; Mintardjo R; Gillissen G; Vogels R; Skeiky YA; Hone DM; Sadoff JC; van der Poll T; Havenga M; Goudsmit J
    Infect Immun; 2007 Aug; 75(8):4105-15. PubMed ID: 17526747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization strategies against pulmonary tuberculosis: considerations of T cell geography.
    Horvath CN; Xing Z
    Adv Exp Med Biol; 2013; 783():267-78. PubMed ID: 23468114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCR6 is a marker for protective antigen-specific cells in the lungs after intranasal immunization against Mycobacterium tuberculosis.
    Lee LN; Ronan EO; de Lara C; Franken KL; Ottenhoff TH; Tchilian EZ; Beverley PC
    Infect Immun; 2011 Aug; 79(8):3328-37. PubMed ID: 21628524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a temperature-restricted, mucosal tuberculosis vaccine in guinea pigs.
    Gupta T; LaGatta M; Helms S; Pavlicek RL; Owino SO; Sakamoto K; Nagy T; Harvey SB; Papania M; Ledden S; Schultz KT; McCombs C; Quinn FD; Karls RK
    Tuberculosis (Edinb); 2018 Dec; 113():179-188. PubMed ID: 30514501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A.
    Stylianou E; Griffiths KL; Poyntz HC; Harrington-Kandt R; Dicks MD; Stockdale L; Betts G; McShane H
    Vaccine; 2015 Nov; 33(48):6800-8. PubMed ID: 26478198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.